SCHEMBL1304565

SCHEMBL1304565

CC(C)(Oc1ccc(NC(=O)Nc2ccc(Cl)c(Cl)c2)cc1)C(=O)O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 2/20 0.59
EPHX2 P34913 2/20 0.59
MEN1 O00255 3/20 0.57
KMT2A Q03164 3/20 0.57
NPC1 O15118 3/20 0.57
HTT P42858 2/20 0.57
LMNA P02545 1/20 0.57
ADORA3 P0DMS8 1/20 0.57
CHRM1 P11229 1/20 0.57
SLC6A2 P23975 1/20 0.57
PDE4A P27815 1/20 0.57
ADRA1A P35348 1/20 0.57
OPRM1 P35372 1/20 0.57
PDE3A Q14432 1/20 0.57
NLRP3 Q96P20 1/20 0.57
CA2 P00918 2/20 0.56
CA9 Q16790 2/20 0.56
CA12 O43570 1/20 0.56
CA1 P00915 1/20 0.56
MAPT P10636 4/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1305530 0.89 PPARA (0.55) EPHX1EPHX2MEN1KMT2ANPC1
SCHEMBL1305000 0.88 MAPT (0.68) MEN1KMT2ANPC1HTTLMNA
SCHEMBL13945701 0.87 EPHX2 (0.65) EPHX1EPHX2MEN1KMT2ANPC1
SCHEMBL805971 0.87 PPARA (0.61) EPHX2MEN1KMT2ANPC1LMNA
SCHEMBL16303954 0.87 PPARA (0.61) EPHX2MEN1KMT2ANPC1LMNA
SCHEMBL9131125 0.87 PPARA (0.52) EPHX2MEN1KMT2ANPC1HTT
SCHEMBL14345472 0.85 PPARA (0.52) EPHX1EPHX2MEN1KMT2ANPC1
SCHEMBL1306107 0.85 PPARA (0.60) EPHX2MEN1KMT2ANPC1HTT
SCHEMBL9303663 0.85 MEN1 (0.57) EPHX1EPHX2MEN1KMT2ANPC1
SCHEMBL1305301 0.84 MEN1 (0.66) MEN1KMT2ANPC1HTTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12065451-B2 Organic electroluminescent materials and devices UNIVERSAL DISPLAY CORPORATION (US) 2024-08-20 US claimed
US-8048896-B2 Inhibit nonenzymatic formation of advanced glycation end-products (AGE) using e.g. aminoguanidine, OPB-9195 [(+/-)-2-isopropylidenehydrazono-4-oxo-thiazolidin-5-yla cetanilide], pyridoxamine, antioxidants, alagebrium, antihypertensives, angiotensin-converting enzyme inhibitors Cell Viable Corporation (US) 2011-11-01 US claimed
EP-1165064-B1 NOVEL INHIBITORS OF FORMATION OF ADVANCED GLYCATION ENDPRODUCTS (AGE'S) HOPE CITY (US) 2004-02-25 EP claimed
US-6337350-B1 CROSSLINKING INHIBITION OF PROTEINS CITY OF HOPE 2002-01-08 US claimed
EP-1165064-A2 NOVEL INHIBITORS OF FORMATION OF ADVANCED GLYCATION ENDPRODUCTS (AGE'S) City of Hope (US) 2002-01-02 EP claimed
WO-2000059875-A2 NOVEL INHIBITORS OF FORMATION OF ADVANCED GLYCATION ENDPRODUCTS (AGE'S) CITY OF HOPE (US) 2000-10-12 WO claimed
US-5268500-A Aromatic urea carboxylated compound MONTEFIORE MEDICAL CENTER (US) 1993-12-07 US claimed
EP-0358724-A4 COMPOUND, COMPOSITION AND METHOD FOR THE REDUCTION OF LIPIDS THE MODIFICATION OF THE AFFINITY OF HEMOGLOBIN FOR OXYGEN AND THE PREVENTION OF PLATELET AGGREGATION. LALEZARI IRAJ (US) 1990-06-05 EP claimed
EP-0358724-A1 COMPOUND, COMPOSITION AND METHOD FOR THE REDUCTION OF LIPIDS THE MODIFICATION OF THE AFFINITY OF HEMOGLOBIN FOR OXYGEN AND THE PREVENTION OF PLATELET AGGREGATION LALEZARI, Iraj (US) 1990-03-21 EP claimed
WO-1988010113-A1 COMPOUND, COMPOSITION AND METHOD FOR THE REDUCTION OF LIPIDS THE MODIFICATION OF THE AFFINITY OF HEMOGLOBIN FOR OXYGEN AND THE PREVENTION OF PLATELET AGGREGATION LALEZARI IRAJ (US) 1988-12-29 WO claimed
US-12065451-B2 Organic electroluminescent materials and devices UNIVERSAL DISPLAY CORPORATION (US) 2024-08-20 US disclosed
CN-218899918-U Portable micro-nano atomizing eye patch 广东多美达智能终端有限公司 2023-04-25 CN disclosed
CN-114630910-A Improved homology-dependent repair genome editing 伊纳瑞农业技术有限公司 2022-06-14 CN disclosed
US-20220056062-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES UNIVERSAL DISPLAY CORPORATION (US) 2022-02-24 US disclosed
US-8053449-B2 Method for inhibiting AGE complex formation Cell Viable Corporation (US) 2011-11-08 US disclosed
US-5093367-A Arylureidophenoxymethylpropionic acids which have activity in dissociation of oxygen from hemoglobin MONTEFIORE MEDICAL CENTER (US) 1992-03-03 US disclosed
EP-0420930-A4 METHOD OF SYNTHESIS AND NOVEL COMPOUNDS FOR PHARMACEUTICAL USES 1991-12-04 EP disclosed
EP-0420930-A1 METHOD OF SYNTHESIS AND NOVEL COMPOUNDS FOR PHARMACEUTICAL USES LALEZARI, Iraj (US) 1991-04-10 EP disclosed
US-4921997-A Method of synthesis and novel compounds for pharmaceutical uses MONTEFIORE MEDICAL CENTER (US) 1990-05-01 US disclosed
WO-1989012622-A1 METHOD OF SYNTHESIS AND NOVEL COMPOUNDS FOR PHARMACEUTICAL USES LALEZARI IRAJ (US) 1989-12-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220056062-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES OSBP, OCIAD2, OCIAD1 EPHX1 1495/4885EPHX2 2411/4885MEN1 1082/4885
US-12065451-B2 Organic electroluminescent materials and devices OSBP, OCIAD2, OCIAD1 EPHX1 1495/4885EPHX2 2411/4885MEN1 1082/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.